IDH1 and acute myeloid leukemia: Ivosidenib also showed a 42.4% CR plus CR with partial hematologic recovery (CRh) rates as monotherapy [3] and a 60.9% CR rate in combination with azacitidine in patients with newly-diagnosed IDH1-mutated AML who were ineligible for standard therapy [35].